At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.

The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.

The deal includes an upfront payment of $20 million. Stereotaxis could pay up to an additional $25 million if certain regulatory and commercial milestones are met.

The once-daily pill received FDA approval on April 1. However, the agency has requested additional data on multiple potential side effects. 

PFA is still quite safe overall. However, new data out of EHRA 2026 suggest cardiologists have much to learn about minimizing risk during treatment. 

SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months. 

Early data linked the device with short crossing times, reduced fluoro exposure and no device-related adverse events.

According to Heartflow, Cleerly's actions represent “one of the most egregious examples of piracy in the medical technology industry.” Cleerly commented on the lawsuit, defending the value and integrity of its products. 

Job growth in cardiology is expected to outpace other healthcare specialties in the years ahead. The demand for new cardiologists is so high, however, that the current shortage is not expected to end anytime soon.

Stryker, one of the world’s largest medtech companies, has agreed to acquire a rising name in the field of intravascular lithotripsy.